Contents of immunizing agents available for use in Canada: Canadian Immunization Guide
For health professionals
Notice
- This CIG chapter has not been updated to contain information regarding COVID-19 vaccines. For this information, refer to the COVID-19 vaccine chapter.
Last partial content update (see Table of Updates): January2020
This chapter was updated to align with changes made to:
- Herpes Zoster (Shingles) Vaccine Chapter in Part 4 based on NACI's Updated Recommendations on the Use of Herpes Zoster Vaccines
- Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020
December 2020: This chapter was updated to align with changes made to:
- Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021
- Meningococcal Vaccine Chapter in Part 4
- Rabies Vaccine Chapter in Part 4
- Recommendations on the use of COVID-19 vaccine(s)
- Smallpox Vaccine Chapter in Part 4
- Information from "Part 5: Passive Immunization" has been incorporated in to Table 2 for the following passive immunizing agents:
- Botulism antitoxin
- Botulism immunoglobulin
- Cytomegalovirus immunoglobulin
- Diphtheria antitoxin
- Hepatitis B Immunoglobulin
- Rabies Immunoglobulin
- Smallpox Immunoglobulin
- Standard Immunoglobulin
- Tetanus Immunoglobulin
- Varicella Immunoglobulin
Last complete chapter revision (see Table of Updates): April 2017
On this page
- Introduction
- Contents of immunizing agents
- Table 1: Types and contents of vaccines available for use in Canada
- Table 2: Types and contents of passive immunizing agents available for use in Canada
Introduction
The following tables provide a comprehensive list of contents of immunizing agents available in Canada. Table 1 lists contents of active vaccines and Table 2 lists contents of passive immunizing agents. Vaccine providers should consult the product label, product leaflet, or product monograph for current product information. Manufacturers provide evidence of vaccine safety and efficacy and receive authorization for the immunizing agent only when it is used in accordance with the product monograph available through Health Canada's Drug Product Database. Information about the vaccine manufacturer/distributor is available in vaccine-specific chapters in Part 4. For more information about immunoglobulins, refer to Basic Immunology and Vaccinology in Part 1.
Contents of immunizing agents
In addition to the active component (antigen or instructions for the antigen in case of vaccines or antibody in case of immunoglobulins), immunizing agents may contain additional ingredients such as adjuvants, preservatives, additives, and traces of other substances.
Adjuvants
An adjuvant is a substance that is added to a vaccine to enhance the resulting immune response and to extend the duration of B and T cell activation. An adjuvant allows a reduction in the amount of antigen per dose or the total number of doses needed to achieve immunity, and helps to improve the immune response in individuals with some degree of immune suppression (for example, the elderly). The adjuvants used in vaccines currently marketed in Canada are:
- aluminum salts (aluminum hydroxide, aluminum phosphate, or aluminum hydroxyphosphate sulfate)
- AS01B (3-O-desacyl-4'-monophosphoryl lipid A [MPL], Quillaja saponaria Molina, fraction 21 [QS-21], cholesterol, dioleoyl phosphatidylcholine [DOPC], disodium phosphate anhydrous, potassium dihydrogen phosphate, sodium chloride, water for injection)
- AS04 (3-O-desacyl-4'-monophosphoryl lipid A adsorbed onto aluminum [as hydroxide salt])
- MF59 (oil-in-water emulsion composed of squalene as the oil phase, stabilized with the surfactants polysorbate 80 and sorbitan trioleate, in citrate buffer).
Preservatives
Chemicals (for example, thimerosal, phenol, 2-phenoxyethanol) may be added to vaccines to prevent serious infections which may result from bacterial or fungal contamination of the vaccine. Most vaccines available for use in Canada do not contain thimerosal.
Other contents of immunizing agents
Other substances that may be found in immunizing agents include:
- Minute amounts of chemicals that are used during the production process, such as for the growth or purification of specific antigens or the inactivation of toxins. For example, antibiotics that prevent contamination during viral cell culture; egg or yeast proteins glycerol, serum, amino acids and enzymes that are needed for the growth of bacteria and viruses; and formaldehyde that is used to inactivate viruses and protein toxins.
- Small amounts of chemicals that support product stability. For example, additives such as potassium or sodium salts, lactose, and polysorbate help control product acidity (pH) and maintain the quality of vaccine antigens.
Brand name | Route | Vaccine type (live; inactivated) |
Immunogen | Adjuvant | Preservative | Potential allergensTable 1 - Footnote 1 | Other materials | Abbreviation |
---|---|---|---|---|---|---|---|---|
Act-HIB® | IM | non-live | Hib | - | - | Tetanus toxoid carrier protein |
|
Hib |
ADACEL® | IM | non-live |
|
Alum | PE | - |
|
Tdap |
ADACEL®-POLIO | IM | non-live |
|
Alum | PE |
|
|
Tdap-IPV |
AFLURIA® TETRA | IM | non-live | Inf | - | TmTable 1 - Footnote 2 |
|
|
IIV4-SD |
AGRIFLU® | IM | non-live | Inf | - | TmTable 1 - Footnote 2 |
|
|
IIV3-SD |
AVAXIM® | IM | Inactivated | HA | Alum |
|
Neomycin |
|
HA |
AVAXIM® Pediatric | ||||||||
BEXSERO® | IM | non-live | Men B | Alum | - |
|
|
4CMenB |
BOOSTRIX® | IM | non-live |
|
Alum | - | - |
|
Tdap |
BOOSTRIX®-POLIO | IM | non-live |
|
Alum | - |
|
|
Tdap-IPV |
CERVARIX® | IM | non-live | HPV | AS04 | - | Latex in plunger stopper of pre-filled syringe |
|
HPV2 |
DUKORAL® | Oral | non-live |
|
- | - | - |
|
Chol-Ecol-O |
ENGERIX®-B | IM | Inactivated | HB | Alum |
|
|
HB | |
ENGERIX®-B Pediatric dose | ||||||||
FLUAD® | IM | Inactivated | Inf | MF59 |
|
|
IIV3-Adj | |
FLUAD Pediatric® | ||||||||
FLUCELVAX®QUAD | IM | Non-Live | INF | TmTable 1 - Footnote 2 | - |
|
IIV4-cc | |
Flulaval™ Tetra | IM | non-live | Inf | - | TmTable 1 - Footnote 2 | IIV4-SD | ||
Flulaval™ Tetra | IM | non-live | Inf | - | TmTable 1 - Footnote 2 |
|
|
IIV4-SD |
FLUMIST® QUADRIVALENT | IN | Live | Inf | - | - |
|
|
LAIV4 |
FLUVIRAL® | IM | non-live | Inf | - | Tm |
|
|
IIV3-SD |
FLUZONE® HD | IM | non-live | Inf | - | - |
|
|
IIV3-HD |
FLUZONE® Quadrivalent | IM | non-live | Inf | - | TmTable 1 - Footnote 2 |
|
|
IIV4-SD |
GARDASIL® | IM | non-live | HPV | Alum | - | Yeast protein |
|
HPV4 |
GARDASIL® 9 | IM | non-live | HPV | Alum | - | Yeast protein |
|
HPV9 |
HAVRIX® | IM | Inactivated | HA | Alum | Neomycin |
|
HA | |
HAVRIX® 720 JUNIOR | ||||||||
HIBERIX® | IM | non-live | Hib | - | - | Tetanus toxoid carrier protein |
|
Hib |
IMOVAX® Polio | SC | non-live | IPV | - | PE |
|
|
IPV |
IMOVAX® Rabies | IM | non-live | Rab | - | - |
|
|
HDCV |
IMVAMUNE® | SC | Live | Vaccinia | - | - |
|
|
- |
INFANRIX hexa® | IM | non-live |
|
Alum | - |
|
|
DTaP-HB-IPV-Hib |
INFANRIX®-IPV | IM | non-live |
|
- | - |
|
|
DTaP-IPV |
INFANRIX®-IPV/Hib | IM | non-live |
|
Alum | - |
|
|
DTaP-IPV-Hib |
INFLUVAC® | IM | non-live | Inf | - | - |
|
|
IIV3-SD |
INFLUVAC® TETRA | SC/IM | non-live | Inf | - | - |
|
|
IIV4-SD |
IXIARO® | IM | non-live | JE | Alum | - | - |
|
JE |
Menactra® | IM | non-live | Men | - | - | Diphtheria toxoid carrier protein |
|
Men-C-ACYW-DT |
Menjugate® | IM | non-live | Men | Alum | - |
|
|
Men-C-C-CRM |
MENJUGATE Liquid | IM | Non-live | Men | Alum |
|
|
Men-C-C-CRM | |
Menveo™ | IM | non-live | Men | - | - | Diphtheria CRM197 toxoid carrier protein |
|
Men-C-ACYW-CRM |
M-M-R® II | SC | Live |
|
- | - |
|
|
MMR |
Moderna COVID-19 Vaccine | IM | Non-live | SARS-CoV-2 | - | - |
|
|
COVID-19 |
NeisVac-C® Vaccine | IM | non-live | Men | Alum | - | Tetanus toxoid carrier protein | Sodium chloride | Men-C-C-TT |
NIMENRIX® | IM | non-live | Men | - | - | Tetanus toxoid carrier protein |
|
Men-C-ACYW-TT |
PEDIACEL® | IM | non-live |
|
Alum | PE |
|
|
DTaP-IPV-Hib |
Pfizer-BioNTech COVID-19 Vaccine | IM | Non-live | SARS-CoV-2 | - | - |
|
|
COVID-19 |
PNEUMOVAX® 23 | SC/IM | non-live | Pneu | - | P | - |
|
Pneu-P-23 |
Prevnar® 13 | IM | non-live | Pneu | Alum | - | Diphtheria CRM197 toxoid carrier protein |
|
Pneu-C-13 |
PRIORIX® | SC/IM | Live |
|
- | - |
|
|
MMR |
PRIORIX-TETRA® | SC/IM | Live |
|
- | - |
|
|
MMRV |
PROQUAD™ | SC | Live |
|
- | - |
|
|
MMRV |
QUADRACEL® | IM | non-live |
|
Alum | PE |
|
|
DTaP-IPV |
RabAvert® | IM | non-live | Rab | - | - |
|
Human serum albumin | PCECV |
RECOMBIVAX HB® | IM | non-live | HB | Alum | - |
|
|
HB |
ROTARIX® | Oral | Live | Rot | - | - | - |
|
Rot-1 |
RotaTeq® | Oral | Live | Rot | - | - | - |
|
Rot-5 |
SHINGRIX | IM | non-live | VZVgE | AS01B | - | - |
|
RZV |
Smallpox (dried)Table 1 - Footnote 3 | ID | Live | Vaccinia | - | - |
|
|
Sma |
Smallpox (frozen)Table 1 - Footnote 4 | - | - | - | - | - | - | - | Sma |
SYNFLORIX® | IM | non-live | Pneu | Alum | - |
|
|
Pneu-C-10 |
Td ADSORBED | IM | non-live |
|
Alum | PE | - |
|
Td |
Td POLIO ADSORBED | IM | non-live |
|
Alum | PE |
|
|
Td-IPV |
TRUMENBA® | IM | Non-live | Men B |
|
MenBf-HBP | |||
TWINRIX® | IM | Inactivated |
|
Alum |
|
|
HAHB | |
TWINRIX® Junior | ||||||||
TYPHIM Vi® | IM | non-live | Typh | - | P | - | Isotonic buffer solution | Typh-I |
VAQTA® | IM | non-live | HA | Alum | - |
|
|
HA |
VARILRIX® | SC | Live | Var | - | - | Neomycin |
|
Var |
VARIVAX® III | SC | Live | Var | - | - |
|
|
Var |
ViVAXIM® | IM | non-live | Typh (HA) | Alum |
|
Neomycin |
|
HA-Typh-I |
Vivotif® | Oral | Live | Typh | - | - | Gelatin |
|
Typh-O |
YF-VAX® | SC | Live | YF | - | - |
|
|
YF |
ZOSTAVAX® | SC | Live | Var | - | - |
|
|
LZV |
Empty boxes indicate that there are no materials of relevance in the product.
|
Abbreviations
Route-
- ID
- intradermal
- IM
- intramuscular
- IN
- intranasal
- SC
- subcutaneous
Immunogen-
- aP
- acellular pertussis
- ap
- acellular pertussis (reduced)
- BCG
- Bacillus Calmette-Guérin
- Chol
- cholera
- D
- diphtheria
- d
- diphtheria (reduced)
- Ecol
- enterotoxigenic Escherichia coli
- Hib
- Haemophilus influenzae type b
- HA
- hepatitis A
- HB
- hepatitis B
- HPV
- human papillomavirus
- Inf
- influenza
- IPV
- inactivated poliomyelitis
- JE
- Japanese encephalitis
- Men
- meningococcus
- Men B
- Neisseria meningitidis Serogroup B protein
- Meas
- measles
- Mumps
- mumps
- Pneu
- pneumococcus
- Rab
- rabies
- Rot
- rotavirus
- R
- rubella
- T
- tetanus
- Typh
- typhoid
- Var
- varicella
- YF
- yellow fever
- Zos
- herpes zoster
Adjuvant-
- Alum
- aluminum-containing adjuvant
- AS01B
- 3-O-desacyl-4'-monophosphoryl lipid A [MPL], Quillaja saponaria Molina, fraction 21 [QS-21], cholesterol, dioleoyl phosphatidylcholine [DOPC], disodium phosphate anhydrous, potassium dihydrogen phosphate, sodium chloride, water for injection
- AS04
- 3-O-desacyl-4'-monophosphoryl lipid A adsorbed onto aluminum (as hydroxide salt)
- MF59
- squalene, polysorbate 80, sorbitan trioleate, sodium citrate, citric acid, water for injection
Preservative-
- CH 2O
- formaldehyde
- P
- phenol
- PE
- 2-phenoxyethanol
- Tm
- thimerosal
Brand name | Route | Passive immunizing agent type | Origin of antibodies | Protects against or treats | Preservative | Potential allergens | Other materials | Abbreviation |
---|---|---|---|---|---|---|---|---|
A dash [ - ] indicates that there are no materials of relevance in the product. | ||||||||
Antidiphtheria serumFootnote 1 | IV | Antitoxin | Horse serum or Horse plasma | D | Type varies with supplier | Equine protein |
|
DAT |
BAT®Footnote 2 | IV | Antitoxin | Horse plasma | B | N/A | Equine protein |
|
BAT |
Baby BIG®Footnote 1 Footnote 2 | IV | Immunoglobulin | Human plasma | B | None | - |
|
BIG-IV |
Cytogam®Footnote 3 | IV | Immunoglobulin | Human plasma | CMV | None | - |
|
CMVIg |
CNJ-016™ | IV | Immunoglobulin | Human plasma | Vac | None | - |
|
VIG |
GamaSTAN®S/D | IM | Immunoglobulin | Human plasma |
|
None |
|
Ig | |
HepaGam B® | IM/IV | Immunoglobulin | Human plasma | HB | None | - |
|
HBIg |
HyperHEP B®S/D | IM | Immunoglobulin | Human plasma | HB | None | - |
|
HBIg |
HYPERRAB®™ S/D | IM/ -local | Immunoglobulin | Human plasma | Rab | None | - |
|
RabIg |
HYPERTET®S/D | IM | Immunoglobulin | Human plasma | Tet | None | - |
|
TIg |
IMOGAM®Rabies Pasteurized | IM/ -local | Immunoglobulin | Human plasma | Rab | None | - |
|
RabIg |
KamRAB™ | IM | Immunoglobulin | Human plasma | Rab | None | - |
|
RabIg |
SYNAGIS®(palivizumab) | IM | Humanized monoclonal antibody | Recombinant DNA technology | RSV | None | - |
|
RSVAb |
VariZIG®™ | IV/ IM | Immunoglobulin | Human plasma | Var | - | - |
|
VarIg |
Notes de bas de page
|
Abbreviations:
Route-
- IM
- intramuscular
- IV
- intravenous
Protects against or treats-
- B
- Botulism
- CMV
- Cytomegalovirus
- D
- diphtheria
- HA
- hepatitis A
- HB
- hepatitis B
- Meas
- measles
- R
- rubella
- Rab:
- rabies
- RSV
- respiratory syncytial virus
- T
- tetanus
- Vac
- vaccinia
- Var
- varicella
- N/A
- Not applicable
Preservative-
- P
- phenol
Selected references
- Keith LS, Jones DE, Chou C. Aluminum toxicokinetics regarding infant diet and vaccinations. Vaccine 2002;20:S13-17.
- Offit PA, Jew RK. Addressing parents' concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 2003;112:1394-97.
Report a problem or mistake on this page
- Date modified: